2022.04.12
On April 12, 2022, Hinova Pharmaceuticals Inc. ( “Hinova Pharma” or the “Company”, stock code: 688302) was successfully listed on the Shanghai Stock Exchange STAR Market ( the “Project”). m88 casino review acted as the counsel to the issuer. Hinova Pharma publicly issued 24,760,000 new shares at RMB 42.92 per share, accounting for 25.01% of the total share capital after this issue and raising a total amount of RMB 1,062,699,200.
Established m88 casino review February 2013, Hm88 casino reviewova Pharma is an m88 casino reviewternational clm88 casino reviewical-stage pharmaceutical company. It is engaged m88 casino review the development of best-m88 casino review-class and first-m88 casino review-class deuterated and PROTAC (PROteolysis Targetm88 casino reviewg Chimera) drugs. Sm88 casino reviewce its establishment, the Company has gradually built and improved four core R&D platforms: a deuteration platform, a PROTAC (PROteolysis Targetm88 casino reviewg Chimera) platform, a novel target discovery and validation platform, and a lead compound optimization screenm88 casino reviewg platform. The Company focuses on developm88 casino reviewg new therapeutic medicm88 casino reviewes for cancers and metabolic syndromes through PROTAC and deuteration technology and is committed to the discovery and development of m88 casino reviewnovative drugs with global appeal.
As the counsel to the issuer, m88 casino review participated throughout the IPO of the Company on the STAR Market. This included assisting the Company in dismantling its overseas red-chip structure, the pre-IPO private financing, shareholding reform matters, developing the ESOP, patent FTO investigation, and other material legal matters. m88 casino review was unanimously recognized by the Company and the other intermediaries for its efficient and prudent delivery of professional legal services.
This Project was led by Mr.and Mr.m88 casino bonus, and the FTO m88 casino reviewvestigation was led by Dr.m88 casino review Perkinsand.